Announcements Trials
Browse Landscape

Phase

Phase 1 5Phase 2 2Phase 1/2 2Phase 3 1

Status

Terminated 2Completed 2Withdrawn 1

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Tumor-Agnostic 2Plasma cell 2Breast 1

Conditions

Neoplasms 4Multiple Myeloma 2Triple Negative Breast Neoplasms 1Recurrence 1

Interventions

pembrolizumab 304Paclitaxel 206Carboplatin 200Gemcitabine 173Cisplatin 139Docetaxel 138Cyclophosphamide 136Nivolumab 129Bevacizumab 118Injections 111fludarabine 96atezolizumab 91Pemetrexed 90Dexamethasone 90Cetuximab 90Fluorouracil 84Irinotecan 77Rituximab 72Capecitabine 72venetoclax 71Azacitidine 70130-nm albumin-bound paclitaxel 67Leucovorin 65Fulvestrant 58Oxaliplatin 57durvalumab 56Trastuzumab 56Lenalidomide 55Ipilimumab 55Midazolam 54

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 1 × INDUSTRY × afuresertib × Clear all
NCT05390710 2024-10-10

PhI to Solid Tumors and PhII to Locally Advanced or mTNBC

Laekna Limited

Phase 1 Completed
21 enrolled
Breast

Triple Negative Breast Neoplasms

NCT02177682 2021-08-11

Study of Afuresertib Monotherapy in Japanese Relapsed Multiple Myeloma Patients

Novartis

Phase 1 Terminated
9 enrolled
Plasma cell

Multiple Myeloma, Neoplasms

NCT02240212 2017-04-11

Study of Afuresertib Combined With Paclitaxel in Gastric Cancer

Novartis

Phase 1 Completed
29 enrolled
Tumor-Agnostic

Neoplasms

NCT02380313 2016-10-06

Dose-Finding Study of Afuresertib Administered in Combination With Either Enzalutamide or Aibraterone

GlaxoSmithKline

Phase 1 Withdrawn
Tumor-Agnostic

Neoplasms

NCT02235740 2016-05-04

A Study Conducted in Subjects With Relapsed/Refractory Multiple Myeloma (MM); to Determine Dose of Afuresertib in Combination With Carfilzomib (Part 1) and to Investigate the Safety, Pharmacokinetic and Clinical Activity of the Combination Compared With Carfilzomib Alone (Part 2)

Novartis

Phase 1 Terminated
1 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡